Bruker Daltonics announced that the Rapid Structure Characterization Laboratory (RSCL) of the Schering-Plough Research Institute (SPRI) has selected the new solariX FTMS platform as a cutting-edge tool for structural characterization and purity assessment of pharmaceuticals under development at SPRI.
Bruker Daltonics explained that the RSCL can be tasked with solving some of the most difficult chemical structure problems encountered during drug development, as well as many day-to-day applications, that companies have for structural characterization of chemical compounds.
Dr. Gary Martin, Distinguished Fellow at Schering Plough and the leader of the RSCL, commented: “The chemical formula provided by the solariX platform for both the complete unknown, as well as pieces of the unknown compound from MSn, is pivotal information that can complement the information derived from NMR spectroscopy. Combining these data can speed the solving of complex structural problems. We look forward to using solariX in our work.”
Dr. Paul Speir, Vice President for FTMS at Bruker Daltonics, stated: “Our solariX FTMS platform offers unmatched mass resolution and flexibility, a wide variety of ionization techniques, the capability to perform MSn experiments with accurate mass measurement at each stage, and is even capable of ion-molecule reactions. All of these capabilities can be useful in solving the extremely difficult structural characterization problems that pharmaceutical scientists routinely encounter.”
Date: May 29, 2009
Source: Bruker Daltonics
Filed Under: Drug Discovery
